Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 861-865

  Manley, Harold J ^a,b   Allcock, Nicole M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Dialysis Clinic Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FERRITIN; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; TRANSFERRIN;

ADULT; AGED; AMBULATORY CARE; ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VOLUME; BODY WEIGHT; CLINICAL ARTICLE; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEMATOCRIT; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MALE; RETROSPECTIVE STUDY; SIDE EFFECT;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTPATIENTS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 0037705723     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.861.32727     Document Type: Article

References (20)

1. Anonymous. U.S. renal data system, USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
2. Manley HJ, McClaran ML, Overbay DK, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003;41:386-93.
3. Manley HJ, Bailie GR, Grabe DW. Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health-Syst Pharm 2000;57:902-6.
4. Morioka R, Emoto M, Tabta T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-13.
5. Bristol-Meyers Squibb Company. Glucophage (metformin) package insert. Princeton, NJ; 2002.
6. Novo Nordisk Pharmaceuticals, Inc. Prandin (repaglinide) package insert. Princeton, NJ; 2002.
7. Novartis Pharmaceuticals Corporation. Starlix (nateglinide) package insert. East Hanover, NJ; 2000.
8. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-5.
9. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, et al. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism 2002;51:44-51.
10. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999;84:3J-10.
11. Shinohara K, Shoiji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894-900.
12. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-92.
13. Young MM, Squassante L, Werner J, Van Marle SP, Dogterom P, Jonkman JH. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol 1999;55:101-4.
14. Anonymous. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1 suppl 1):S182-238.
15. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport E, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
16. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrin Metab 2001;86:280-8.
17. Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7.
18. Aronoff S, Rosenblatt S, Braithwaite S, Egen JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605-11.
19. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8.
20. Manley HJ, Overbay DK, McClaran M, Bender W, Muther RS. Medication record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis clinic. Pharmacotherapy 2003;23:231-9.